<DOC>
	<DOCNO>NCT00117481</DOCNO>
	<brief_summary>This 3-arm , multicenter , double-blind , randomize , placebo-controlled study evaluate efficacy DR-2001 endometriosis-related symptom , primarily nonmenstrual pelvic pain , 12-week treatment period .</brief_summary>
	<brief_title>Evaluation DR-2001 Management Endometriosis-Related Pelvic Pain</brief_title>
	<detailed_description>This multicenter , double-blind , randomize , placebo-controlled study design evaluate ability DR-2001 produce beneficial change endometriosis-related symptom , primarily nonmenstrual pelvic pain , 12-week treatment period . The overall study duration patient 20 week . Patients meet study entrance criterion randomly assign one three treatment group . The change endometriosis-related clinical symptom assess two way : combine physician/patient assessment also patient self-assessment . Patients undergo gynecologic exam study visit .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<criteria>Surgically sterilize ( patient partner ) , willing use condom throughout study , otherwise risk pregnancy Diagnosis endometriosis within last 5 year Moderate severe nonmenstrual pelvic pain Premenopausal Not pregnant breastfeed Regular ( 2435 day ) menstrual cycle least 2 month Undiagnosed abnormal genital bleed Any contraindication use hormonal therapy Prior surgery endometriosis GnRH analog therapy within 5 month Use estrogens and/or progestin within 2 month Pain symptom unrelated endometriosis Any contraindication use vaginal delivery system</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>endometriosis</keyword>
	<keyword>pelvic pain</keyword>
	<keyword>hormonal treatment</keyword>
</DOC>